LA JOLLA, CA, United States

Intrinsic Lifesciences, Llc

www.intrinsiclifescience.co
LA JOLLA, CA, United States
SEARCH FILTERS
Time filter
Source Type

Patent
Intrinsic Lifesciences, Llc | Date: 2017-08-02

The present application relates to humanized antibodies that specifically bind to hepcidin and methods of using the humanized antibodies. Another aspect relates to humanized antibodies which bind hepcidin and regulate iron homeostasis. Another aspect relates to the use of humanized antibodies which bind hepcidin for the treatment of a disease or condition associated with hepcidin.


Schmidt P.J.,Harvard University | Racie T.,Alnylam Pharmaceuticals | Westerman M.,Intrinsic Lifesciences, Llc | Fitzgerald K.,Alnylam Pharmaceuticals | And 2 more authors.
American Journal of Hematology | Year: 2015

β-thalassemias result from diminished β-globin synthesis and are associated with ineffective erythropoiesis and secondary iron overload caused by inappropriately low levels of the iron regulatory hormone hepcidin. The serine protease TMPRSS6 attenuates hepcidin production in response to iron stores. Hepcidin induction reduces iron overload and mitigates anemia in murine models of β-thalassemia intermedia. To further interrogate the efficacy of an RNAi-therapeutic downregulating Tmprss6, β-thalassemic Hbbth3/+ animals on an iron replete, an iron deficient, or an iron replete diet also containing the iron chelator deferiprone were treated with Tmprss6 siRNA. We demonstrate that the total body iron burden is markedly improved in Hbbth3/+ animals treated with siRNA and chelated with oral deferiprone, representing a significant improvement compared to either compound alone. These data indicate that siRNA suppression of Tmprss6, in conjunction with oral iron chelation therapy, may prove superior for treatment of anemia and secondary iron loading seen in β-thalassemia intermedia. © 2015 The Authors.


The invention provides compositions and methods for measuring human serum hepcidin levels. The invention provides methods for the oxidative refolding of a hepcidin polypeptide to a form that is mature, bioactive and folded as in the native configuration and molecular mass; a method for measuring the level of native, bioactive hepcidin in a vertebrate animal.


Grant
Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase I | Award Amount: 700.34K | Year: 2013

DESCRIPTION (provided by applicant): Acute kidney injury (AKI) is a common, severe complication of cardiopulmonary bypass (CPB) assisted surgeries, and include coronary artery bypass grafts, valve replacements, aortic aneurisms, and organ transplants. Elderly patients, diabetics, and chronic kidney disease (CKD) patients, have very high risk of developing AKI postoperatively. One million CPB surgeries yearly result in thousands of AKI-related deaths and disabilities involving renal replacement therapy (RRT), cumulatively costing billions. Existing renal markers confirming loss of function (e.g. serum creatinine) in AKI are very late markers (1-3 days) for diagnosis of AKI. Few biomarkers (e.g. NGAL, KIM-1) are commercially available for early prediction ofAKI. Early biomarkers and rapid tests predicting the severity of post-CPB AKI will enable patient stratification, earlier therapeutic interventions, and drug development for AKI Recently, we have shown that hepcidin is a small peptide (2.78kD) produced inthe liver and excreted in urine and may be a good biomarker for AKI post CPB-assisted surgery. In two 100 patient clinical trials with our collaborators in Australia (NCT00910221; Prowle et al. 2012) and Germany (NCT00672334; Haase-Felietz et al. 2011), plasma and urine samples were taken at baseline, 6hr and 24hr from baseline. In contrast to established biomarkers of AKI, plasma creatinine (pCr) and neutrophil gelatinase-associated lipocalin (NGAL), in both these studies urinary hepcidin (uHep; ng/ml) anduHep adjusted for urine creatinine (uHep/uCr; ng/mg) was inversely correlated with severity of AKI when scored by RIFLE criteria (based on pCr). AKI-free patients had highly elevated levels of uHep and uHep/uCr at 6hr that increased through 24hr. uHep anduHep/uCr increased 3- to 7-fold compared to patients with AKI (P = 0.004, P = 0.002) at 6hr in the German study with a AUC-ROC 0.80; 0.88, respectively, for prediction of AKI-free recovery and an AUC-ROC 0.81; 0.88, respectively, for prediction of RRT-free recovery. These data support uHep and uHep/uCr as a promising biomarker of AKI-free recovery at 6 hours, much earlier than existing biomarkers such as plasma creatinine, urine output volume, and GFR. However, for a biomarker to be useful for diagnosis ofAKI, it must be measured and the data returned to the surgeon and ICU staff quickly as there are few established clinical interventions for AKI. We propose development of a portable, quantitative lateral flow device (LFD) that can rapidly determine urineand plasma hepcidin concentrations rapidly and quantitatively in the ICU. We have recently discovered and characterized two new mouse anti-hepcidin monoclonal antibodies (MAb) in ongoing SBIR research (PA 08- 114; 2-R44-DK083843-02). For our last submission we made a prototype hepcidin H1 MAb LFD using a gold- conjugated hepcidin tracer that we ultimately abandoned. The specific aims for our revised Phase I research and development efforts are, 1). Assess urinary and plasma hepcidin, NGAL, and KIM-1 in 1800de-identified time-matched samples from a prospective clinical study and perform extensive statistical analysis, and 2) Develop a rapid, quantitative lateral flow device (LFD) suitable for plasma and urine hepcidin and test the new device in the clinicalsamples from the prospective study to evaluate utility of a hepcidin LFD for post-CPB AKI. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: One million Cardiopulmonary Bypass (CPB) surgeries (cardiac grafting, valve replacement, transplants) occur annually and Acute Kidney Injury (AKI) following removal from bypass causes thousands of deaths, longer hospital stays, long-term disabilities, and billions in costs. Current biomarkers cannot predict AKI quickly enough following CPB although new clinical data suggests that urine hepcidin may be a novel, early biomarker of the severity of AKI. Development of a rapid, precise, quantitative lateral flow medical device to measure urine hepcidin in the ICU may allow earlier intervention, novel drugs and therapies to be developed, and valuable clinical benefits to high-risk CPB patients, ultimately saving lives and reducing healthcare costs.


Muller K.F.,University Hospital of Tuebingen | Lorenz L.,University Hospital of Tuebingen | Poets C.F.,University Hospital of Tuebingen | Westerman M.,Intrinsic Lifesciences, Llc | Franz A.R.,University Hospital of Tuebingen
Journal of Pediatrics | Year: 2012

Objectives: To evaluate whether hepcidin concentrations in serum (Hep (S)) and urine (Hep (U)) correlate with iron metabolism, erythropoiesis, and inflammation in preterm infants. Study design: Thirty-one preterm infants (23-32 weeks gestational age) were included. The concentration of the mature, 25 amino-acid form of hepcidin was determined by enzyme-linked immunosorbent assay in serum, urine, blood counts, reticulocytes, and iron measurements. Results: Median (IQR) Hep (S) was 52.4 (27.9-91.9) ng/mL. The highest values were measured in patients with systemic inflammation. Hep (S) and Hep (U) correlated strongly (P =.0007). Hep (S) and Hep (U) also correlated positively with ferritin (P =.005 and P =.0002) and with reticulocyte hemoglobin content (P =.015 and P =.015). Hep (S) and Hep (U) correlated negatively with soluble transferrin receptor/ferritin-ratio (P =.005 and P =.003). Infants with lower hemoglobin concentrations and higher reticulocyte counts had lower Hep (S) (P =.0016 and P =.0089). Conclusion: In sick preterm infants, iron status, erythropoiesis, anemia, and inflammation correlated with the mature 25 amino-acid form of hepcidin. Further evaluation of Hep (U) for non-invasive monitoring of iron status in preterm infants appears justified. Copyright © 2012 Mosby Inc.


Grant
Agency: Department of Health and Human Services | Branch: National Institutes of Health | Program: SBIR | Phase: Phase II | Award Amount: 4.41M | Year: 2014

DESCRIPTION provided by applicant Disorders of iron metabolism are among the most common human diseases During the last decade rapid progress has been made in understanding the molecular basis of iron homeostasis and its disorders The peptide hormone hepcidin has emerged as the master regulator of iron metabolism Dysregulation of hepcidin is the principal or contributing factor in most systemic iron disorders In humans primary overproduction of hepcidin due to genetic deficiency of a negative regulator of hepcidin transcription the membrane protein matriptase TMPRSS leads to iron refractory iron deficiency anemia IRIDA IRIDA is a disorder of excessive hepcidin synthesis relative to plasma iron and can be diagnosed by measuring hepcidin levels rather than by DNA sequencing the current confirmatory diagnosis There is a well recognized unmet need for a robust and widely available clinical assay for serum hepcidin but progress towards this goal has been slowed by the poor immunogenicity of hepcidin Intrinsic Life Sciences ILS developed and validated the worldandapos s first RUO serum hepcidin immunoassay competitive ELISA C ELISA that relied on a finite supply of high quality rabbit polyclonal antibodies This first generation hepcidin assay was instrumental in showing that the IRIDA phenotype is caused by inappropriately elevated hepcidin in relation to plasma iron levels and after preliminary data analysis we have demonstrated that this assay can definitively distinguish with high sensitivity and specificity individuals with IRIDA due to TMPRSS mutations from a normal control population of children and adults children and adults with uncomplicated iron deficiency ID and a highly selected population of individuals who have ID that is resistant to oral iron therapy who have been referred to as andquot rule outandquot IRIDA During Phase II research ILS discovered key monoclonal antibodies to hepcidin and developed two robust C ELISAs These prototype new generation andapos wetandapos assays have an excellent dynamic range possess ideal precision and linearity characteristics and display LLOQ LLOD and EC values and intra and inter assay CVandapos s that parallel or exceeds those of our current polyclonal RUO C ELISA Preliminary analysis of de identified IRIDA patient samples have demonstrated that MAb and the NT biotinylated hepcidin tracer yield excellent sensitivity specificity and AUROC that parallel our polyclonal RUO C ELISA We propose to continue to develop the Hepcidin IRidA Competeandquot IVD as a desiccated microplate assay and demonstrate its clinical utility for diagnosis of IRIDA in anemic patients we will enroll Under ISO GMP regulatory guidelines we will complete pre manufacturing Randamp D on our hepcidin IVD finalize design features and produce test lots of assay components confirm reagent performance finalize the Device Master Record and file pre IDE materials to the FDA We will manufacture compliance lots conduct continuous FDA compliant manufacturing performance and quality studies To demonstrate its clinical use we will seek FDA pre IDE guidance finalize design of a prospective clinical trial to be performed at Boston Childrenandapos s Hospital and test the Hepcidin IRidA Competeandquot IVD for diagnostic discrimination between TMPRSS patients with IRIDA and clinically indistinguishable anemic patients enrolled in the trial PUBLIC HEALTH RELEVANCE The founders of Intrinsic Life Sciences ILS pioneered discovery of hepcidin the master iron regulatory hormone in humans and developed the worldandapos s first validated serum hepcidin immunoassay as well as described its key role regulating dietary iron absorption and iron recycling With NIH Phase II funding our team discovered specific monoclonal antibodies MAb to hepcidin and used one MAb to make two prototype serum hepcidin diagnostic tests that are suitable for FDA approval With NIH Phase II B funding ILS will complete pre commercialization Randamp D and select one prototype assay for cGMP ISO manufacturing of the Hepcidin IRidA Competeandquot IVD perform a prospective clinical trial in collaboration with Boston Childrenandapos s Hospital and clinically validate our diagnostic testfor definitive differential diagnosis of a rare genetic iron disorder Iron Refractory Iron Deficiency Anemia IRIDA that has clinical characteristics common in anemic pediatric adolescent patients without the disorder FDA approval of the Intrinsic Hepcidin IRidA Competeandquot IVD will enable rapid diagnosis of IRIDA without expensive genetic testing or extensive clinical work ups


Patent
Intrinsic Lifesciences, Llc | Date: 2014-03-13

The present application relates to antibodies that specifically bind to hepcidin and methods of using the antibodies. Another aspect relates to antibodies which bind hepcidin and regulate iron homeostasis. Another aspect relates to the use of humanized antibodies which bind hepcidin for the treatment of a disease or condition associated with hepcidin.


Trademark
Intrinsic Lifesciences, Llc | Date: 2016-03-14

96-well plate enzyme linked immunosorbent assay (ELISA) for detection of human hepcidin for research and clinical use.


Patent
Intrinsic Lifesciences, Llc | Date: 2010-06-10

The invention provides compositions and methods for measuring human serum hepcidin levels. The invention provides methods for the oxidative refolding of a hepcidin polypeptide to a form that is mature, bioactive and folded as in the native configuration and molecular mass; a method for measuring the level of native, bioactive hepcidin in a vertebrate animal.


Loading Intrinsic Lifesciences, Llc collaborators
Loading Intrinsic Lifesciences, Llc collaborators